Company Description
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2021 |
| IPO Date | May 8, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Gary Glick |
Contact Details
Address: 51 Sleeper Street, Suite 800 Boston, Massachusetts 02210 United States | |
| Phone | 617 865 9628 |
| Website | odysseytx.com |
Stock Details
| Ticker Symbol | ODTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1882782 |
| CUSIP Number | 67613T104 |
| ISIN Number | US67613T1043 |
| Employer ID | 86-3384382 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gary D. Glick Ph.D. | Founder, President, Chief Executive Officer and Director |
| Jason Haas M.B.A. | Chief Financial Officer |
| Collin Todd | Senior Vice President of Strategy and Business Development |
| Prof. Eicke Latz M.D., Ph.D. | Scientific Co-Founder |
| Dr. Kim Lewis Ph.D. | Scientific Co-Founder |
| Dr. Felix Meissner Ph.D. | Scientific Co-Founder |
| Dr. Florian.I Schmidt Ph.D. | Scientific Co-Founder |
| Jolie M. Siegel J.D. | Executive Vice President, General Counsel and Secretary |
| Dr. Natalie Dales Ph.D. | Chief of Research Operations and Portfolio Strategy |
| Dr. Joseph McDonald Ph.D. | Chief Data Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 10-Q | Quarterly Report |
| Jun 17, 2026 | 8-K | Current Report |
| Jun 5, 2026 | SCHEDULE 13G | Filing |
| May 18, 2026 | SCHEDULE 13G | Filing |
| May 18, 2026 | SCHEDULE 13D | Filing |
| May 18, 2026 | SCHEDULE 13D | Filing |
| May 15, 2026 | SCHEDULE 13D | Filing |
| May 15, 2026 | SCHEDULE 13D | Filing |
| May 11, 2026 | 8-K | Current Report |